-
Something wrong with this record ?
Tumor-specific histone signature and DNA methylation in multiple myeloma and leukemia cells
V. Foltankova, S. Legartova, S. Kozubek, E. Bartova
Language English Country Slovakia
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22489701
DOI
10.4149/neo_2012_058
Knihovny.cz E-resources
- MeSH
- Chromatin Immunoprecipitation MeSH
- Epigenesis, Genetic genetics MeSH
- Fluorescent Antibody Technique MeSH
- Histones genetics MeSH
- Leukemia genetics MeSH
- Humans MeSH
- DNA Methylation MeSH
- Multiple Myeloma genetics MeSH
- Cell Line, Tumor MeSH
- Promoter Regions, Genetic genetics MeSH
- Gene Expression Profiling MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Understanding the epigenetics of tumor cells is of clinical significance for the treatment of cancer, and thus, chemists have focused their efforts on the synthesis of new generation of inhibitors of histone deacetylases (HDACs) or methylation-specific enzymes as novel important anti-cancer drugs. Here, we tested whether the histone signature and DNA methylation in multiple myeloma (MM) and leukemia cells is tumor-specific as compared with that in non-malignant lymphoblastoid cells. We observed a distinct histone signature in c-myc, Mcl-1, and ribosomal gene loci in MOLP8 MM and K562 leukemia cells, when compared with lymphoblastoid cells. Histone and DNA methylation patterns in MOLP8 cells were partially modified by the clinically promising HDAC inhibitor, vorinostat. In comparison with lymphoblastoid WIL2NS cells, MOLP8 cells and K562 cells were characterized by an absence of the gene silencing marker H3K9me2 in the c-myc and ribosomal genes. However, high levels of H3K27me3 were detected in the promoters and coding regions of selected genomic regions in these cells. Treatment by vorinostat increased the level of DNA methylation at the c-myc promoter, and this alteration was accompanied by a decrease in c-MYC protein. In MOLP8 cells, vorinostat significantly increased the H3K9 acetylation in the Mcl-1 coding regions and promoter. Both MOLP8 and K562 leukemia cells were characterized by decreased levels of H3K9me2 in the Mcl-1 gene as compared with lymphoblastoid WIL2NS cells. Lower levels of H3K9me1 in the Mcl-1 promoter, however, were specific for MM cells as compared with the other cell types studied. In other MM and leukemia cell lines, COLO677, OPM2, and U937, the ribosomal genes were less prone to epigenetic heterogeneity as compared to the c-myc and Mcl-1 proto-oncogenes. Taken together, these data describe both tumor-specific and loci-specific histone signature and DNA methylation profiles.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12034587
- 003
- CZ-PrNML
- 005
- 20160904075131.0
- 007
- ta
- 008
- 121023s2012 xo f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.4149/neo_2012_058 $2 doi
- 035 __
- $a (PubMed)22489701
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Foltánková, Veronika $7 xx0121909 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, CZ-612 65, Brno, Czech Republic
- 245 10
- $a Tumor-specific histone signature and DNA methylation in multiple myeloma and leukemia cells / $c V. Foltankova, S. Legartova, S. Kozubek, E. Bartova
- 520 9_
- $a Understanding the epigenetics of tumor cells is of clinical significance for the treatment of cancer, and thus, chemists have focused their efforts on the synthesis of new generation of inhibitors of histone deacetylases (HDACs) or methylation-specific enzymes as novel important anti-cancer drugs. Here, we tested whether the histone signature and DNA methylation in multiple myeloma (MM) and leukemia cells is tumor-specific as compared with that in non-malignant lymphoblastoid cells. We observed a distinct histone signature in c-myc, Mcl-1, and ribosomal gene loci in MOLP8 MM and K562 leukemia cells, when compared with lymphoblastoid cells. Histone and DNA methylation patterns in MOLP8 cells were partially modified by the clinically promising HDAC inhibitor, vorinostat. In comparison with lymphoblastoid WIL2NS cells, MOLP8 cells and K562 cells were characterized by an absence of the gene silencing marker H3K9me2 in the c-myc and ribosomal genes. However, high levels of H3K27me3 were detected in the promoters and coding regions of selected genomic regions in these cells. Treatment by vorinostat increased the level of DNA methylation at the c-myc promoter, and this alteration was accompanied by a decrease in c-MYC protein. In MOLP8 cells, vorinostat significantly increased the H3K9 acetylation in the Mcl-1 coding regions and promoter. Both MOLP8 and K562 leukemia cells were characterized by decreased levels of H3K9me2 in the Mcl-1 gene as compared with lymphoblastoid WIL2NS cells. Lower levels of H3K9me1 in the Mcl-1 promoter, however, were specific for MM cells as compared with the other cell types studied. In other MM and leukemia cell lines, COLO677, OPM2, and U937, the ribosomal genes were less prone to epigenetic heterogeneity as compared to the c-myc and Mcl-1 proto-oncogenes. Taken together, these data describe both tumor-specific and loci-specific histone signature and DNA methylation profiles.
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a chromatinová imunoprecipitace $7 D047369
- 650 _2
- $a metylace DNA $7 D019175
- 650 _2
- $a epigeneze genetická $x genetika $7 D044127
- 650 _2
- $a fluorescenční protilátková technika $7 D005455
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a histony $x genetika $7 D006657
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leukemie $x genetika $7 D007938
- 650 _2
- $a mnohočetný myelom $x genetika $7 D009101
- 650 _2
- $a promotorové oblasti (genetika) $x genetika $7 D011401
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Legartová, Soňa $7 _AN046546 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
- 700 1_
- $a Kozubek, Stanislav, $d 1953- $7 ola2003204933 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, CZ-612 65, Brno, Czech Republic
- 700 1_
- $a Bártová, Eva $7 xx0028314 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, CZ-612 65, Brno, Czech Republic
- 773 0_
- $w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 59, č. 4 (2012), s. 450-462
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22489701 $y Pubmed
- 910 __
- $a ABA008 $b A 1194 $c 659 $y p $z 0
- 990 __
- $a 20121023 $b ABA008
- 991 __
- $a 20160904075439 $b ABA008
- 999 __
- $a ok $b bmc $g 956597 $s 792084
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 59 $c 4 $d 450-462 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
- LZP __
- $b NLK122 $a Pubmed-20121023